Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Hematology"
DOI: 10.1007/s00277-024-06033-y
Abstract: The treatment of older patients with acute myeloid leukemia (AML) considered unfit for receiving intensive chemotherapy is challenging. Based on the hypothesis that addition of the broad tyrosine kinase inhibitor (TKI) midostaurin could improve the… read more here.
Keywords: aml; decitabine; midostaurin; intensive chemotherapy ... See more keywords
Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
Sign Up to like & getrecommendations! Published in 2018 at "Biochemistry"
DOI: 10.1021/acs.biochem.8b00727
Abstract: The multitargeted protein kinase inhibitor midostaurin is approved for the treatment of both newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and KIT-driven advanced systemic mastocytosis. AML is a heterogeneous malignancy, and investigational drugs targeting FLT3… read more here.
Keywords: profile midostaurin; kinase; midostaurin metabolites; comparison kinase ... See more keywords
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/leu.2017.234
Abstract: Patients with advanced systemic mastocytosis (SM) (e.g. aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL)) have limited treatment options and exhibit reduced survival. Midostaurin is an oral multikinase… read more here.
Keywords: median follow; advanced systemic; systemic mastocytosis; patients advanced ... See more keywords
Recurrent Hyperbilirubinemia with Midostaurin during Consolidation in a Patient of AML with FLT3 Mutation and Review of Literature for Alternative Maintenance Strategy
Sign Up to like & getrecommendations! Published in 2025 at "Indian Journal of Medical and Paediatric Oncology"
DOI: 10.1055/s-0043-1772255
Abstract: Abstract Midostaurin-induced hyperbilirubinemia during consolidation chemotherapy is uncommon. Dose-modification strategy for midostaurin in presence of hyperbilirubinemia remains undefined. We report a case of a young woman diagnosed as acute myeloid leukemia having normal cytogenetics with… read more here.
Keywords: recurrent hyperbilirubinemia; consolidation; hyperbilirubinemia midostaurin; hyperbilirubinemia ... See more keywords
Antileukemic effects of midostaurin in acute myeloid leukemia – the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2017.1275564
Abstract: ABSTRACT Introduction: Midostaurin is a multikinase inhibitor that inhibits receptor tyrosine kinases (Flt3, CD117/c-kit, platelet-derived growth factor receptor, vascular endothelial growth factor receptor 2) as well as non-receptor tyrosine kinases (Frg, Src, Syk, Protein kinase… read more here.
Keywords: antileukemic effects; myeloid leukemia; stromal cells; inhibition ... See more keywords
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2054801
Abstract: ABSTRACT Introduction FLT3 inhibitors have been recently introduced as novel treatment targets in patients with FLT3-mutated acute myeloid leukemia (AML). Midostaurin is an oral multikinase inhibitor that targets multiple receptor tyrosine kinases including FLT3 and… read more here.
Keywords: mutated acute; flt3 mutated; acute myeloid; midostaurin ... See more keywords
Midostaurin abrogates CD33‐directed UniCAR and CD33‐CD3 bispecific antibody therapy in acute myeloid leukaemia
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.15975
Abstract: Combinatory therapeutic approaches of different targeted therapies in acute myeloid leukaemia are currently under preclinical/early clinical investigation. To enhance anti‐tumour effects, we combined the tyrosine kinase inhibitor (TKI) midostaurin and T‐cell mediated immunotherapy directed against… read more here.
Keywords: cd33; cell; myeloid leukaemia; acute myeloid ... See more keywords
Single Institution Phase 1 Study on Combination Therapy of Midostaurin and Panobinostat in Acute Myeloid Leukemia - the Interim Report
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-120327
Abstract: Background: Midostaurin is a non-specific FLT3 inhibitor which showed anti-leukemic activity against both FLT3 mutated as well as unmutated acute myeloid leukemia (AML) in early phase studies. Panobinostat, a potent oral pandeacetylase inhibitor had also… read more here.
Keywords: anti leukemic; study; flt3; cycle ... See more keywords
FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1672
Abstract: Context: FLT3 mutated (FLT3m) AML with co-occurring mutations in DNMT3a and NPM1 (triple mutated) have been identified to be a subset with poor prognosis. However, the evidence for this comes from trials predating the routine… read more here.
Keywords: year; flt3; triple mutated; aml ... See more keywords
Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12061574
Abstract: Acute myeloid leukemia (AML) is a hematopoietic stem-cell-derived leukemia with often successive derived driver mutations. Late onset acquisition of internal tandem duplication in FLT3 (FLT3-ITD) at a high variant allele frequency often contributes to full… read more here.
Keywords: myeloid leukemia; midostaurin; midostaurin gilteritinib; acute myeloid ... See more keywords
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Fungi"
DOI: 10.3390/jof8060583
Abstract: The potential drug-drug interactions of midostaurin may impact the choice of antifungal (AF) prophylaxis in FLT3-positive acute myeloid leukemia (AML) patients. To evaluate the incidence of invasive fungal diseases (IFD) during the treatment of FLT3-mutated… read more here.
Keywords: mutated aml; incidence; flt3 mutated; incidence invasive ... See more keywords